Tovorafenib is under clinical development by Day One Biopharmaceuticals and currently in Phase II for Craniopharyngioma. According to GlobalData, Phase II drugs for Craniopharyngioma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Tovorafenib LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tovorafenib overview
Tovorafenib (Ojemda) acts as an antineoplastic agent. It is formulated as tablets and suspension for oral route of administration. Ojemda is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric lowgrade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
Tovorafenib (TAK-580 (MLN2480)) is under development for the treatment of solid tumors such as glioma, relapsed pediatric low-grade glioma, Langerhans-cell histiocytosis, craniopharyngioma and malignant glioma. It is administered through oral route. The drug candidate acts by targeting pan-Raf kinases A-Raf, B-Raf and C-Raf. It was also under development for the treatment of solid tumors like metastatic melanoma, melanoma,and non-small cell lung cancer.
Day One Biopharmaceuticals overview
Day One Biopharmaceuticals is a biopharmaceutical company. It primarily focuses on pediatric oncology research and drug development. The company’s lead product candidate Tovorafenib, which is used to treat patients with pLGG, a type of pediatric cancer. Day One Biopharmaceuticals also offers product candidates in various stages of clinical trials, including DAY301, a PTK7 targeted ADC and VRK1. Its products are primarily used in the healthcare industry, specifically in the treatment of pediatric and adult cancers. The company operates in the US. Day One Biopharmaceuticals is headquartered in Brisbane, California, the US.
For a complete picture of Tovorafenib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
